Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics

Abstract

Due to their mechanism of action, the new oral anticoagulants are named direct oral anticoagulants (DOACs). Dabigatran is a selective, competitive, direct inhibitor of thrombin (Factor IIa) while rivaroxaban, apixaban and edoxaban act by directly inhibiting the activated Factor X (FXa) in a selective and competitive manner. DOACs have a relatively short half-life and almost immediate anticoagulant activity, and rapidly reach the plasma peak concentration. Therefore, they do not need a phase of overlapping with parenteral anticoagulants. After their withdrawal, their removal is sufficiently rapid, although influenced by renal function. Dabigatran is the only DOACs to be administered as a pro-drug and becomes active after drug metabolization. The route of elimination of dabigatran is primarily renal, whereas FXa inhibitors are mainly eliminated by the biliary-fecal route. The drug interactions of DOACs are mainly limited to drugs that act on P-glycoprotein for dabigatran and on P-glycoprotein and/or cytochrome P3A4 for anti-Xa. DOACs have no interactions with food. Given their linear pharmacodynamics, with a predictable dose/response relationship and anticoagulant effect, DOACs are administered at a fixed dose and do not require routine laboratory monitoring.

Downloads

Download data is not yet available.
Published
2013-12-24
Keywords:
new oral anticoagulants, dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban, pharmacokinetics, pharmacodynamics, pharmacology.
Statistics
Abstract views: 4457

PDF: 1388
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Masotti, L., & Campanini, M. (2013). Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics. Italian Journal of Medicine, 7(8s), 1-7. https://doi.org/10.4081/itjm.2013.s8.1